Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database

This article has been corrected. Please see: Corrections in J Manag Care Spec Pharm. 23(4):493 BACKGROUND: Real-world data comparing tofacitinib with biologic disease-modifying antirheumatic drugs (bDMARDs) are limited. OBJECTIVE: To compare characteristics, treatment patterns, and costs of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Harnett, James, Gerber, Robert, Gruben, David, Koenig, Andrew S., Chen, Connie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397820/
https://www.ncbi.nlm.nih.gov/pubmed/27882833
http://dx.doi.org/10.18553/jmcp.2016.22.12.1457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397820/
https://www.ncbi.nlm.nih.gov/pubmed/27882833
http://dx.doi.org/10.18553/jmcp.2016.22.12.1457

Ejemplares similares